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Inadequate intra  cellular glucocorticoid activity, referred 
to as critical illness-related corticosteroid insuﬃ   ciency, 
typically results in an exaggerated proinﬂ  ammatory 
response [1]. Patients with severe sepsis or septic shock 
are therefore frequently treated with exogenous gluco-
corti  coids. While there are large geographic variations in 
the prescription of glucocorticoids for sepsis, up to 50% 
of intensive care unit patients receive such therapy [2]. 
Despite over 30 years of investigation and over 20 meta-
analyses, the use of glucocorticoids in patients with sepsis 
remains extremely controversial and recommendations 
are conﬂ  icting.
Th   e most important recent studies are that of Annane 
and colleagues [3] and the Corticosteroid Th  erapy of 
Septic Shock (CORTICUS) study [4]. Both of these 
studies have important limitations: 24% patients received 
etomidate in the study by Annane and colleagues, where-
as 19% received etomidate in the CORTICUS study. Th  e 
beneﬁ  t of steroids in the study by Annane and colleagues 
may have been restricted largely to those patients who 
received etomidate [5]. Furthermore, only patients with 
‘refractory septic shock’ were enrolled in the Annane 
study whereas, as a result of an overwhelming selection 
bias, only approximately 5% of eligible patients were 
enrolled in the CORTICUS study [6]. A more recent 
study found no beneﬁ  t from a 7-day course of 40 mg of 
prednisolone in patients hospitalized with community-
acquired pneumonia [7].
In the study by Annane and colleagues [3], patients 
received 50 mg of hydrocortisone intravenously every 
6 hours for 7 days, whereas in the CORTICUS study [4], 
patients received this dose for 5 days, followed by a taper-
ing oﬀ   over a further 5 days. Recently, two longi  tudinal 
studies in patients with severe community-acquired 
pneumonia found high levels of circulating inﬂ  ammatory 
cytokines 3 weeks after clinical resolution of sepsis [8,9]. 
Th  ese data suggest that patients with severe sepsis may 
have pro  longed immune dysregulation (even after clinical 
recovery) and that a longer course of corticosteroids may 
be required. Th   e use of a continuous infusion of hydro-
cortisone has been reported to result in better glycemic 
control with less variability of blood glucose concen-
tration [10]. Th   is may be clinically relevant as it has been 
demonstrated that an oscillating blood glucose level is 
associated with greater oxidative injury than sustained 
hyperglycemia [11]. Indeed, a number of reports indicate 
that glucose variability may be an independent predictor 
of outcome in critically ill patients [12]. A continuous 
infusion of glucocorticoid may, however, result in greater 
suppression of the hypothalamic-pituitary-adrenal axis. 
Furthermore, diﬀ   erent glucocorticoids diﬀ  erentially 
aﬀ  ect gene transcription and have diﬀ  ering pharma  co-
dynamic eﬀ   ects. Conse  quently, the preferred gluco-
corticoid and the optimal dosing strategy in patients with 
septic shock remain to be determined.
Evidence-based medicine is deﬁ  ned as the use of the 
best current scientiﬁ   c evidence in making decisions 
about the care of individual patients. Owing to the dearth 
of high-level evidence, it is not possible to make strong 
evidence-based recommendations on the use of gluco-
corticoids in patients with sepsis. Th  erefore, at this 
juncture, it is useful to summarize what we know, what 
we think we know, and what we do not know in order to  © 2010 BioMed Central Ltd
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Abstract
An intact hypothalamic-pituitary-adrenal axis with 
eff  ective intracellular glucocorticoid anti-infl  ammatory 
activity is essential for host survival following exposure 
to an infectious agent. Glucocorticoids play a major 
role in regulating the activity of nuclear factor-
kappa-B, which has a crucial and generalized role in 
inducing cytokine gene transcription after exposure 
to an invading pathogen. Severe sepsis is, however, 
associated with complex, hypothalamic-pituitary-
adrenal axis alterations, which may result in decreased 
production of cortisol as well as glucocorticoid tissue 
resistance.
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information is summarized in Table 1.
In summary, the risk/beneﬁ  t ratio of glucocorticoids 
should be determined in each patient. A course (7 to 
10 days) of low-dose hydrocortisone (200 mg/day) should 
be considered in vasopressor-dependent patients (dosage 
of norepinephrine or equivalent of greater than 0.1 μg/kg 
per minute) within 12 hours of the onset of shock [1]. 
Steroids should be stopped in patients whose vasopressor 
dependency has not improved with 2 days of gluco-
corticoids. While the outcome beneﬁ  t of low-dose gluco-
corti  coids remains to be determined, such a strategy 
decreases vasopressor dependency and appears to be safe 
(no excess mortality, superinfections, or acute myopathy). 
Infection surveillance is critical in patients treated with 
corticosteroids, and to prevent the rebound phenome-
non, the drug should be weaned slowly. At this time, 
glucocorticoids appear to have a limited role in patients 
who have sepsis or severe sepsis and who are at a low risk 
of dying.
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  •  Treatment with glucocorticoids may reduce the risk of post-traumatic stress disorder [19].
What we do not know
  •  Which patients with severe sepsis/septic shock should be treated with glucocorticoids?
  •  Should treatment with glucocorticoids be based on the results of a cosyntropin stimulation test?
  •  What is the treatment window? Twenty-four hours?
  •  How does one accurately diagnose adrenal insuffi   ciency and inadequate cellular glucocorticoid activity?
  •  What is the optimal dosing schedule of glucocorticoids?
  •  Which glucocorticoid – methylprednisolone or hydrocortisone – should be used?
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